Background Our recent studies suggested that the chromodomain helicase DNA binding protein 1-like (CHD1L) gene plays an oncogenic role in human hepatocellular carcinoma. protein expression in the primary ovarian lesions is 4, while the score in the metastasis is 7. The difference between the levels of CHD1L expression in the primary lesions and in the metastatic lesions was statistically MSX-122 supplier significant (P <0.05, Table ?Table22). Figure 1 The protein expression patterns of CHD1L in primary ovarian lesions and in metastatic leisions. (A) Negative expression of CHD1L protein was observed in a primary ovarian lesions (case 75), in which less than 10% tumor cells revealed positive immunostaining … Table 2 The expression of CHD1L protein in ovarian primary lesions and corresponding metastatic lesions Association of CHD1L protein expression with clinic-pathological parameters In this study, according to the staining index above, protein expression MSX-122 supplier with a scoring index of 4 (median score of CHD1L protein expression in the primary ovarian lesions) is defined as positive expression. The associations between CHD1L expression in primary ovarian carcinomas and several clinico-pathological variables are assessed and displayed in Table ?Table1.1. The positive expression of CHD1L protein expression increasingly presented from mucinous/serous ovarian carcinoma to others types of tumor, including undifferentiated ovarian carcinoma. There was no significant difference between CHD1L protein expression and other clinicopathological features, such as patients age, histological grade, FIGO stage and residual tumor (P>0.05, Table ?Table11). Relationship between clinicpathologic variables, CHD1L protein expression, and ovarian carcinoma patient survival: univariate survival analysis In univariate MSX-122 supplier survival analysis, Kaplan-Meier survival curves and P-values for these curves were manipulated by log-rank method. Kapla-Meier analysis demonstrated a significant impact of well-known clinicopathological prognostic features such as histological grade, FIGO stage (P< 0.05, Table ?Table3)3) and residual tumor (P< 0.05, Table ?Table3).3). A statistically impaired overall survival was observed in patients with CHD1L-positive compared to patients with CHD1L-negative tumors. Mean overall survival time was 97.4 months for patients Rabbit Polyclonal to CDC25B (phospho-Ser323) with CHD1L-negative expression compared to only 66.7 months for patients with CHD1L-positive expression (P< 0.05, Table ?Table3,3, Figure ?Figure22). Table 3 Clinical pathogical parameters and expression of CHD1L for prognosis of 102 patients with ovarian carcinoma by univariate survival analysis (log-rank test) Figure 2 Survival curve for 102 ovarian carcinoma patients according to CHD1L protein expression status (log-rank test). Overall survival, probability of survival of all patients with ovarian carcinoma: negative expression, n=50; positive expression, n=52. Independent prognostic factors of epithelial ovarian carcinoma: multivariate cox regression analysis A multivariate statistic analysis based on the Cox proportional hazard model was used to test the independent prognostic value of each clinicopathological feature (Table ?(Table4).4). Positive expression of CHD1L protein, as well as other clinicopathological variables (FIGO stage and residual tumor) which were significant by univariate analysis, was included in multivariate analysis. The CHD1L protein was discovered to be an independent prognostic factor for poor overall survival (P< 0.01, Table ?Table44). Table 4 Multivariate analysis on overall survival (Cox regression model) Relationship between clinicpathologic variables, CHD1L protein expression, and ovarian carcinoma patient survival: receiver operating characteristic curve (ROC) analysis The ROC for each clinicopathological parameter clearly reveal the point on the curve closest to (0.0, 1.0) which maximizes both sensitivity and specificity for the outcome. The ROC analysis for each clinicopathological variables and CHD1L expression (area under MSX-122 supplier the curve [AUC] =0.622, P=0.05) is carried out to evaluate the patients survival status (Figure ?(Figure33). Figure 3 ROC curve analysis for different clinicopathological parameters and CHD1L protein expression was performed to evaluate the survival status. FIGO stage (area under the curve [AUC] =0.755, P<0.001), CHD1L protein expression ([AUC] =0.622, P<0.05), ... Discussion CHD1L, the candidate oncogene, has been isolated from 1q21 amplicon and found frequently amplified in hepatocellular carcinoma (HCC). Amplification.